#1REDDY NYSE American: MYO ELLELLA INVESTOR PRESENTATION JANUARY 2024 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics myomo my own motion 1#2Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Legal Disclaimer myomo my own motion This presentation contains forward-looking statements regarding the trading of the Company's common stock on the NYSE American, the Company's plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Company's financial position and projections of future operating results, and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the Company's management and its knowledge of the relevant market. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. Forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties and other factors. These risks and uncertainties include, among others, risks related to the Company's liquidity and financial position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. 2#3Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials THE LEADING DEVICE TO ENABLE A PARALYZED ARM TO MOVE AGAIN. MORE THAN 2,000 MYOPRO'S DELVIERED TO PATIENTS: MY OWN MOTION my mo myomo my own motion 3#4Overview Market Opportunity Product Line & Evidence Commercial Scale Up Causes of Upper Extremity Paralysis Major Dx Stroke/CVA Traumatic Brain Injury ➤ Spinal Cord Injury Brachial Plexus Injury SCI Insurance Reimbursement Financials - Stroke — TBI Other Dx Cerebral Palsy myomo my own motion <-BPI Multiple Sclerosis ALS Spinal Muscular Atrophy Acute Flaccid Myelitis 4#5Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials https://www.youtube.com/watch?v=vVrA9Mown DQ -2:43 5%bc G #WCVB CC myomo my own motion 5#6Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Defining the US Target Market New incidences: US: 800,000 strokes/yr. + other Dx 6-12 mos. Rehab Therapy Prevalence Population (Chronic Arm Paralysis) Stroke Spinal Cord Injury Living Brachial Plexus myomo my own motion Expected to approximately double as we are now able to serve Medicare Part B beneficiaries Addressable Market At Home Medically Qualified Insurance Reimbursement Patient Interest 1/3 Enter Injury Prevalence Group Traumatic Brain Injury Source: Christopher and Dana Reeve Foundation Survey, National Stroke Association, World Health Organization, and Myomo base model estimates Cerebral Palsy Multiple Sclerosis ALS etc. Medicare UnitedHealthcare Medicare Solutions VA US. Department of Veterans Affairs BlueCross BlueShield 6#7Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials MyoPro Powered Arm Brace: How it Works ➤ MyoPro uses advanced sensor technology as a brain-computer interface to detect the user's intention to move via the body's electromyogram (EMG) signal ➤ Myomo's proprietary control algorithms interpret the strength of the patient's EMG signal, and our microprocessor-based system can amplify the EMG signal by a factor of 100,000x Lightweight motors in the device are activated enabling the patient to move their impaired arm through their own volition קווין Massachusetts Institute of Technology HARVARD MEDICAL SCHOOL MyoPro rewards patient with movement Patient's brain is the controller How the MyoPro Works р EMG signal processing myomo my own motion Non-invasive sensing 7#8Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Enabling a Paralyzed Arm to Move Again myome Franzisk ALKOHOLE NATURTRUBE https://vimeo.com/781545268/da823e7df8?share=copy https://vimeo.com/781548558/76b59ad742?share=copy myomo my own motion 8#9Overview Market Opportunity Product Line & Evidence Commercial Scale Up Recent Clinical Research Insurance Reimbursement Financials myomo my own motion VA US. Department of Veterans Affairs MAYO CLINIC Kessler REHABILITATION CENTER American Heart Association. Myoelectric Arm Orthosis in Motor Learning-Based Therapy for Chronic Deficits After Stroke and Traumatic Brain Injury Svetlana Pundik, Jessica McCabe, Margaret Skelly, Ahlam Salam Jonathan Naft, Zhengyi Chen, Curtis Tatsuoka and Stefania Fatone Application of a myoelectric elbow flexion assist orthosis in adult traumatic brachial plexus injury: patient perspectives China M. Wetter". Jason S. Egginton, Axander Y. She and Kenton Rauman The Utilization Effects of Powered Wearable Orthotics in Improving Upper Extremity Function in Persons with SCI: A Case study Ghaith J. Andewis, Ph.D., Steven Kinhblum, MD, Guang Yue, Ph.D. Weeks Weeks Weeks Weeks Figure 1. Case 1 (A) baseline clinical photographs 15 months after in- jury demonstrating elbow and shoulder flexion. B, Clinical photographs 22 months after initial injury, 7 months after rehab with an MLO dem- onstrating elbowe and shoulder flexion. 50 40 30 20 10 0 Active elbow-joint angle (degrees) ROM With MyoMo ROM without MyoMo Fig 3. The active ROM of elbow-joint against gravity with and without UE-MPWO (Myo-Pro). Guidelines for Adult Stroke Rehabilitation and Recovery A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association "For individuals with more severe paresis, the potential for recovery of upper extremity function is greatly reduced, particularly later after stroke. Robotic therapy can deliver larger amounts of upper extremity movement practice for these individuals. There are a variety of types of upper extremity robots, consisting primarily of workstation devices used in a rehabilitation facility but also including some wearable exoskeletal devices that can be used in a home environment. A Cochrane review updated in 2012 found that upper limb robotic therapy provided benefit with regard to ADLs and arm function but not arm muscle strength." 9#10Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials New Clinical Research Accepted for Publication Screen viewed by user Myoelectric Arm Orthosis Assists Functional Activities: Boeps EMG- Bops Pre- Tops EMG- EMG senson Finger flexion Grasping an object with paretic limb Result Unsuccessful Without MyoPro Objects grasped Result: Successful Wh MyoPro stration by Cleveland FES Center A 3-Month Home Use Outcome Report Results: Statistically significant and clinically meaningful improvements were observed on the functional tasks. By three months, participants were able to use the MyoPro to accomplish the tasks, reduce the amount of time spent to complete the tasks, and had a higher probability of success as compared to without the MyoPro. With the MyoPro, participants showed significant improvement in overall task completion and completed the tasks in a significantly decreased time as compared to without the MyoPro The DASH and QuickDASH OUTCOME MEASURE User's Manual Third Edition Disabilities of the Arm, Shoulder and Hand Influence of a Myoelectric Arm Orthosis. A Minimum 6 to 17-Month Retrospective Home Use Study On Subjects 65 And Older Using The DASH Outcome Measure (Medicare-Age Population) Results: Subjects had an average improvement of 18 points on the DASH validated outcome measure. Results were clinically significant for a range of patients Ages 66 to 77 with the MyoPro intervention between 2 and 12 years after the onset of their diagnosis. Subjects recovering from arm impairment show an improvement in the DASH self reported score of their ability to complete activities in their home myomo my own motion 10#11Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Go-to-Market Approach: How a Patient Obtains a MyoPro Lead Generation & Evaluation Reimbursement Approval MyoPro Custom Fabrication myomo Delivery & Payment my own motion soweg My right for yout Find out if MyoPro is right for your Of Cours 91 Shaw Medicare myopro New MyoPro 2+ BlueCross Medicare BlueShield Advantage Plans Remote Measurement and In-House Manufacturing Referral to OT for training MyoCare Coaches 11#12Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Cost-Effective TV Advertising for Target Demographic Do you know someone with a paralyzed arm? myomo my own motion https://www.youtube.com/shorts/ym8FZLwW0ql 11#13Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Go-to-Market Approach: Multi-Channel, Emphasis on Direct Billing and International Sales myomo my own motion Q3 2023 Product Revenue % 6% myomo my own motion Sales Channels: In-House Patient Delivery & Direct Billing O&P Providers (U.S. & Int'l) VA Medical Centers 23% 2% 69% ■ Direct Billing US O&P ■International O&P VA 13#14Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials International Update: Activity in Key Markets New Rep added in UK myomo my own motion FDA CE Strong growth in Germany since SHI now covers 90% of population. Japan Patent Issued China JV company established - 19.9% Equity Interest for MYO shareholders China patents issued Launch of JV Operations underway Australia O&Ps starting to order Created with mapchart.net 14#15Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Reimbursement Update HCPCS Codes L8701, L8702 for MyoPro Issued January 2019 CMS CENTERS FOR MEDICARE & MEDICAID SERVICES Expanded Access for Medicare Advantage Beneficiaries Case-by-Case Pre-Authorization Certain Commercial Payers Reimburse for MyoPro Focusing on Patients with Favorable Insurance Plans ➤ Based on Case-by-Case Medical Necessity myomo my own motion UnitedHealthcare Medicare Solutions Senior Insured Population 50% 50% ■Medicare Part B Med. Advantage Source: Kaiser Family Foundation and AARP BlueCross BlueShield Cigna XAetna 15#16Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Reimbursement Update (Continued) Military Approved for Veterans 70 VAMC's have ordered MyoPro's Medicare Part B - BIG NEWS! myomo VA U.S. Department of Veterans Affairs TRIC ARE® my own motion ➤ CMS Published Rule that reclassifies the MyoPro in the Brace Category as of 1/1/24. Published preliminary fees of $31,745 for the Motion W and $62,457 for the Motion G. Final fees expected to be published by the end of February 2024. ➤ Finalizing the fee will open up the Part B Market (50% of Seniors). CMS CENTERS FOR MEDICARE & MEDICAID SERVICES Now that the MyoPro is reimbursed lump sum, we're ramping deliveries in Q1. 16#17Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Reimbursement Status: International Markets myomo my own motion Germany: Reimbursement for the MyoPro is on a case-by-case basis, with insurance companies often paying for a six-month trial to demonstrate the benefit to the patient, followed by full payment for the device in over half of these trial cases Several positive rulings by the Social Court stating that Statutory Health Insurance (SHI) firms such as Barmer must reimburse for the MyoPro Australia: National Disability Insurance Scheme (NDIS) has now approved reimbursement for the MyoPro, which should lead to additional sales in the country Other Markets: Reimbursement is obtained by working through local O&P distribution partners on a case-by-case basis (UK, Italy, Denmark) T< Die Techniker BARMER ndis 17#18Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Key Milestones Driving Revenue Growth Revenues $M China JV license revenue, myomo my own motion MYO LISTED myomo MYO Commercial Scale-up IPO Begins 2.4 1.6 1 Record Int'l revenue Expanded # of Payers and VAMC's Record Int'l and VA Revenue 15.6 19.1-19.3 Pivot to 13.9 Direct Billing, CMS CENTERS FOR MEDICARE & MEDICAID SERVICES Higher ASP; EU Launch 7.6 HCPCS Codes Issued 3.8 2016 2017 2018 2019 2020 2021 2022 2023 18#19Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials myomo my own motion Backlog and Pipeline are Leading Indicators of Revenue 250 200 150 100 50 53 Backlog 1200 230 1000 164 154 800 131 600 816 400 200 Pipeline 1046 0 0 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 9/30/2022 9/30/2023 ➤ Patient pipeline in each period now only reflects patients with payers that have previously reimbursed for the MyoPro. Q4 2023 backlog includes medically qualified Medicare patients 19#20Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials myomo my own motion P&L and Key Balance Sheet Metrics P&L Key Balance Sheet Metrics ($000's) Product Revenue License Revenue Total Revenue COGS Actual Actual Q3'23 Q3'22 Actual 2022 Actual 2021 Actual Actual ($000's) Q3'23 Q2'23 $ 5,030 $ 3,968 50 $ 14,555 $ 13,856 1,000 Cash & Investments $ 11,120 $ 8,956 5,080 3,968 15,555 13,856 Working Capital 10,265 8,293 1,591 1,331 5,302 3,544 Net Book Value 11,023 8,820 3,489 2,637 10,253 10,312 Shares Outstanding 68.7% 66.5% 65.9% 74.4% 35,266 668 * 27,932 668 Gross Profit Gross Margin Operating Expenses: R&D 717 691 2,482 SG&A 4,796 4,765 18,443 Total 5,513 5,456 20,925 2,557 18,023 20,580 Operating Loss $ (2,024) $ (2,819) $ (10,672) $ (10,268) Int income Other expense Income Taxes (112) (34) (88) 15 71 22 67 - 46 23 70 89 5 11 49 104 Net Loss $ (2,029) $ (2,830) $ (10,721) $ (10,372) Warrants Outstanding * Includes unexercised pre-funded warrants 20#21Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Capital Requirements and Cash Flow Breakeven myomo my own motion It is achievable to be cash flow breakeven on a quarterly basis by the fourth quarter of 2024. Requirements: Final published fees by CMS for the MyoPro product line are not significantly lower than the currently published preliminary fees. We are able to add clinical, manufacturing and reimbursement capacity to serve additional volume as planned. No unforeseen supply chain disruptions impacting deliveries and revenue Assuming the above, we believe our existing cash plus the net proceeds received from the recently completed offering would be sufficient to achieve cash flow breakeven and no additional equity capital would be required for liquidity. 21#22Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials myomo my own motion Drivers of Revenue Growth Increased Marketing in US and Germany Medicare Reimbursement New International Markets New Product Introduction for Continued Revenue Growth Expand sales Obtain Medicare in Germany / Part B coverage EU Increase penetration of US Market Launch China JV Introduce MyoPal for Pediatrics 22#23Overview Market Opportunity Product Line & Evidence Commercial Scale Up Insurance Reimbursement Financials Leadership Team & Board of Directors Management Team Members Paul R. Gudonis Chairman & CEO Scaled multiple tech co's, largest from $5M to $1.2B revenue (BBN/Genuity) David Henry, CFO Raised nearly $900M in capital for public companies Micah Mitchell Chief Commercial Officer Grew sales 10x at several custom DME businesses Dr. Harry Kovelman Chief Medical Officer Track record of expanding patent access for new technologies Malcolm Bock VP of Engineering and Product Strategy Experienced Medical Device Engineering Executive Barry Camrell VP of QA/RA Established quality systems for U.S. and int'l markets John Frijters Managing Director - International Experienced executive O&P Europe - based Kathy Sawyers, PT, ATP Sr. Dir. Clinical Outcomes Oversees clinician training and user support Joseph Chicoskie Dir. - Marketing Has led evolution of Myomo's marketing strategy Courtney Accorsi, MS, OTR/L Built Dept. of Patient Advocacy to process 10x growth in claim volume myomo my own motion Board of Directors Thomas Kirk Lead Independent Director Former CEO, Hanger Clinics Amy Knapp Board Member Experienced Health Insurance Industry Executive Thomas Crowley Board Member Experienced Med Device CEO Milton Morris Board Member Former President & CEO, Neuspera Medical; Boston Scientific exec1 Yitzchak Jacobovitz Board Member Partner and Lead Healthcare Analyst AIGH Capital Management 23 1#24Thank You! For Additional Information: Paul R. Gudonis, CEO [email protected] 617-401-2623 David Henry, CFO [email protected] 508-344-5235 myomo my own motion 24